FAST DISSOLVING TABLETS OF PIMOZIDE: DESIGN, OPTIMIZATION AND IN VITRO CHARACTERIZATION

被引:1
作者
Kamisetti, Raja Rajeswari [1 ]
Mekala, Moses [2 ]
Muvvala, Sudhakar [2 ]
Penmatsa, Durga Bhavani [1 ]
机构
[1] Jawaharlal Nehru Tech Univ, Vishnu Inst Pharmaceut Educ & Res, Hyderabad 502313, Andhra Pradesh, India
[2] Osmania Univ, Malla Reddy Coll Pharm, Maisammaguda 500014, Secunderabad, India
来源
INDONESIAN JOURNAL OF PHARMACY | 2015年 / 26卷 / 02期
关键词
Pimozide; Tourette's syndrome; fast dissolving tablets; Kyron T 314; direct compression;
D O I
10.14499/indonesianjpharm26iss2pp114
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
As precision of dosing and patient compliance become an important prerequisite for a long-term treatment of Tourette's syndrome there is a need to develop formulation for this drug, which overcomes problems such as difficulty in swallowing, inconvenience in administration while travelling and patient's acceptability. The present work was undertaken with a view to develop a fast dissolving tablets of Pimozide using Kyron T-314 as super-disintegrant along with Avicel PH 102 as diluent by response surface method using direct compression. Drug-excipient compatibility studies were confirmed by FTIR Spectroscopy. The tablets were evaluated for hardness, friability, weight variation, wetting time, disintegration time and uniformity of content and in vitro dissolution. Based on evaluating parameters, formulation prepared by using 4.5% Kyron T-314 with 11.5% Avicel PH-102 was selected as optimized formulation and Formulation (F3) had disintegration time of 7.63 +/- 0.25s and percentage cumulative drug release of 81.60 after 10min. The formulations were further studied and confirmed for their stability. Hence it was concluded that direct compression using Kyron T-314 superdisintegrant and Avicel PH 102 was simple and economic technique which can be used for formulation of fast dissolving tablets of Pimozide.
引用
收藏
页码:114 / 120
页数:7
相关论文
共 11 条
[1]   Evaluation of rapidly disintegrating tablets prepared by a direct compression method [J].
Bi, YX ;
Sunada, H ;
Yonezawa, Y ;
Danjo, K .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1999, 25 (05) :571-581
[2]  
Biradar SS, 2006, INT J PHARMACEUT, V24, P1
[3]  
Chaudhari PD, 2005, IND DRUGS, V42, P641
[4]  
Dobetti L, 2001, PHARM TECHNOL N AM, V6
[5]  
Eddy Clare M, 2011, Ther Adv Neurol Disord, V4, P25, DOI 10.1177/1756285610390261
[6]  
FOG R, 1980, J NEURAL TRANSM-SUPP, V16, P211
[7]  
Habib W, 2000, CRIT REV THER DRUG, V17, P61
[8]  
James FL, 2002, LANCET, V360, P1577
[9]   Long-acting injectable risperidone: Efficacy and safety of the first long-acting atypical antipsychotic [J].
Kane, JM ;
Eerdekens, M ;
Lindenmayer, JP ;
Keith, SJ ;
Lesem, M ;
Karcher, K .
AMERICAN JOURNAL OF PSYCHIATRY, 2003, 160 (06) :1125-1132
[10]   PIMOZIDE - ADVERSE REACTION AND PROLONGED HALF-LIFE [J].
LOGAN, FA ;
HERRINGTON, RN ;
MACKIE, MMS ;
RUBIN, PC .
BRITISH JOURNAL OF PSYCHIATRY, 1982, 140 (APR) :433-434